Join our daily newsletter At The Bell to receive exclusive market insights
- Profit share agreement to commercialise proprietary men’s sexual health range in Australia
- Targets large and growing men’s sexual health market
- EVE supplies proprietary, patent-pending technology
- EVE entitled to 75% of the profit available for distribution
EVE Health Group (ASX: EVE) is confident its binding master compounding and profit share agreement with Optimal Pharmacy Plus Stafford is an important step in commercialising its proprietary technology in the Australian men’s health market.
.png)
The company says men’s sexual health is a large and growing market, and one that patients increasingly access through telehealth.
The agreement provides EVE with a pathway to supply its proprietary range to patients through a pharmacy-led model. An Australian study of more than 100,000 men aged 45 and over found that around 61% reported some degree of erectile dysfunction and around one in three reported moderate or complete erectile dysfunction.
Globally, erectile dysfunction was projected to affect around 322 million men by 2025, and the global erectile dysfunction treatment market is estimated at approximately US$5.7 billion in 2026.
The structure is capital-light, EVE supplies its formulation technology and the pharmacy partner compounds, dispenses and delivers the product, so EVE can earn revenue from its intellectual property without the cost and time of building its own compounding operation, while keeping the option to pursue a registered product in the future.
The range is based on EVE’s patent-pending nano-emulsion technology, designed to treat both erectile dysfunction and premature ejaculation, two conditions that commonly occur together. EVE retains ownership of the formulation and all related intellectual property, including any improvements made under the agreement.
The agreement is separate from and does not affect, the company’s Libbo vardenafil oral soluble film program, which continues along its planned bioequivalence and registration pathway.
“This agreement is an important milestone for EVE. We are taking our proprietary, patent-pending technology to market in Australia through a capital-light model, with a strong pharmacy partner that will support supply,” CEO, Ben Rohr, said
“We keep full ownership of our IP, we establish a pathway to revenue, and we retain the option to pursue a registered product as well. We see this as the first step in unlocking value from our formulation technology.”
EVE will now work with Optimal to complete the readiness steps for first supply and engage telehealth partners to reach patients. Prescribing decisions will remain with independent clinicians, with each product compounded for an individual patient against a valid prescription.
EVE was up 12.0% to 1.4¢. Mkt cap $4.404M.
Join the discussion: See what HotCopper users are saying about EVE Health Group and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
